Literature DB >> 5467552

Livedo reticularis in patients with parkinsonism receiving amantadine.

C N Shealy, J B Weeth, D Mercier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5467552

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  7 in total

Review 1.  The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review.

Authors:  Markus Kraemer; Dieter Linden; Peter Berlit
Journal:  J Neurol       Date:  2005-08-26       Impact factor: 4.849

Review 2.  Current drug therapy for Parkinson's disease. A review.

Authors:  R J Coleman
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

3.  Livedo reticularis during amantadine treatment.

Authors:  D I Vollum; J D Parkes; D Doyle
Journal:  Br Med J       Date:  1971-06-12

Review 4.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

5.  Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study.

Authors:  A Barbeau; H Mars; M I Botez; M Joubert
Journal:  Can Med Assoc J       Date:  1971-07-10       Impact factor: 8.262

Review 6.  Adverse effects of antiparkinsonian drugs.

Authors:  J D Parkes
Journal:  Drugs       Date:  1981-05       Impact factor: 9.546

7.  Livedo reticularis associated with dapsone therapy in a patient with chronic urticaria.

Authors:  Z A Wafai; Qadrie Zulfkar; Farah Sameem
Journal:  Indian J Pharmacol       Date:  2014 Jul-Aug       Impact factor: 1.200
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.